Relation between apolipoprotein E phenotype and the changes in lipids during tamoxifen treatment

Endocrine Journal

Volumn 45, Issue 2, 1998, Pages 255-259

  Hozumi, Yasuo ^a   Kawano, Mikihiko ^a   Saito, Tsuyoshi ^a   Miyata, Michio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Apolipoprotein E phenotype; Breast cancer; Lipid metabolism; Tamoxifen

Indexed keywords

APOLIPOPROTEIN E; TAMOXIFEN;

ARTICLE; BREAST CANCER; CASE REPORT; CHOLESTEROL BLOOD LEVEL; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; PHENOTYPE; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0031837520     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.45.255     Document Type: Article

References (17)

1. Rossner S, Wallgern A (1984) Serum lipoproteins and proteins after breast cancer surgery and effects of tamoxifen. Atherosclerosis 52: 339-346.
2. Enck RE, Rois CN (1984) Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer 53: 2607-2609.
3. Bertelli G, Pronzato P, Amoroso D, Cusimano MP Conte PF Montagna G, Bertolini S, Rosso R (1988) Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 12: 307-310.
4. Thangaraju M, Kumar K, Gandhirajan R, Sachdanandam P (1994) Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer 73: 659-663.
5. Dnistrian AM, Schwartz MK, Greenberg EJ, Smith CA Schwartz DC (1993) Effect of tamoxifen on serum cholesterol and lipoproteins during chemohormonal therapy. Clin Chim Acta 223: 43-52.
6. Bokiniec AD, Wojtacki J, Skokowski, Kortas B (1994) The effect of tamoxifen treatment on serum cholesterol fractions in breast cancer women. Neoplasma 41: 13-16.
7. Menotti A, Scanga M, Moris G (1994) Serum triglycerides in the prediction of coronary artery disease (an Italian experience). Am J Cardiol 73: 29-32.
8. Davignon J, Gregg RE, Sing CF (1988) Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis 8: 1-21.
9. Utermann G, Hess M, Steinmetz A (1977) Polymorphism of apolipoprotein E and occurrence of dysbetailpoproteinemia in man. Nature 269: 604-607.
10. Hozumi Y, Kawano M, Miyata M (1997) Severe hypertriglyceridemia caused by tamoxifentreatment after breast cancer surgery. Endocr J 44: 745-749.
11. Brun LD, Gagne C, Rousseau C, Moorjani S, Lupien P-J (1986) Severe lipemia induced by tamoxifen. Cancer 57: 2123-2126.
12. Mahley RW, Innerarity TL (1983) Lipoprotein receptors and cholesterol homeostasis. Biochim Biophys Acta 737: 197-222.
13. Innerarity TL, Weisgraber KH, Arnold KS, Rall SCJr, Mahley RW (1984) Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation. J Biol Chem 259: 7261-7267.
14. Rall SC-Jr, Weisgraber KH, Innerarity TL, Mahley RW (1982) Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci USA 79: 4696-4700.
15. Kesaniemi YA, Ehnholm C, Mietinenn TA (1987) Intestinal cholesterol absorption efficiency in man is related to apolipoprotein E phenotype. J Clin Invest 80: 578-581.
16. Utermann G (1987) Apolipoprotein E polymorphism in health and disease. Am Heart J 113: 433-440.
17. Ueki A, Kawano M, Namba Y, Kawakami M, Ikeda K (1993) A high frequency of apolipoprotein E4 isoprotein in Japanese patients with late-onset nonfamilial Alzheimer's disease. Neurosci Lett 163: 166-168.